Nasdaq Repl News Today

Replimune Group (NASDAQ:REPL – Get Free Report) and Zura Bio (NASDAQ:ZURA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Risk & Volatility Replimune Group has a […]

Profund Advisors LLC lifted its position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 19.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,557 shares of the company’s stock after purchasing an additional 5,045 shares during the quarter. Profund Advisors […]

Loomis Sayles & Co. L P grew its stake in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 8.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,290,450 shares of the company’s stock after purchasing an additional 103,223 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Replimune Group […]

Replimune Group (NASDAQ:REPL – Get Free Report) issued its earnings results on Thursday. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.12, Briefing.com reports. Replimune Group Stock Up 0.9 % Shares of REPL traded up $0.07 during trading hours on Friday, hitting $7.79. The stock had […]

Replimune Group (NASDAQ:REPL – Free Report) had its target price decreased by Barclays from $50.00 to $13.00 in a research report report published on Wednesday morning, Benzinga reports. Barclays currently has an overweight rating on the stock. A number of other brokerages also recently weighed in on REPL. Wedbush reaffirmed an outperform rating and issued […]

Camber Capital Management LP increased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 24.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,550,000 shares of the company’s stock after acquiring an additional 300,000 shares […]

Caption Management LLC purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,968 shares of the company’s stock, valued at approximately $766,000. Caption Management LLC owned approximately 0.06% […]

Mirae Asset Global Investments Co. Ltd. boosted its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 6.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,226 shares of the company’s stock after purchasing an additional 1,649 shares […]

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) have received an average recommendation of “Buy” from the six analysts that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have issued a report on the stock in […]

Wedbush reissued their outperform rating on shares of Replimune Group (NASDAQ:REPL – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has a $52.00 price objective on the stock. Wedbush also issued estimates for Replimune Group’s Q3 2024 earnings at ($0.90) EPS, FY2024 earnings at ($3.57) EPS, FY2025 earnings […]